Connect Biopharma Initiates Phase 2 Seabreeze STAT Studies for Asthma and COPD, Showcasing Promising Data on Rademikibart's Efficacy and Safety
Reuters
Aug 13
<a href="https://laohu8.com/S/CNTB">Connect Biopharma</a> Initiates Phase 2 Seabreeze STAT Studies for Asthma and COPD, Showcasing Promising Data on Rademikibart's Efficacy and Safety
Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company focused on inflammatory diseases, has announced the initiation of Phase 2 Seabreeze STAT studies. These studies are evaluating rademikibart as an adjunct treatment for acute exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The company has already presented positive data supporting rademikibart's potential efficacy and safety at major medical meetings, specifically ATS 2025 and EAACI 2025. Additionally, Connect Biopharma has submitted a new drug application for rademikibart for the treatment of atopic dermatitis $(AD)$ to China's National Medical Products Administration via Simcere, their exclusive licensee in Greater China. This move is part of Connect Biopharma's strategic efforts to expand its market presence and enhance investor engagement by transitioning from an American Depositary Receipt program to directly listing ordinary shares on Nasdaq.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9511293-en) on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.